High Plasma Levels of Macrophage Migration Inhibitory Factor Predict Future Cardiovascular Events in Patients with Impaired Glucose Tolerance or Type 2 Diabetes Mellitus

被引：0
|
作者：
Makino, Aritaka [1 ]
Kodama, Yasushi [1 ]
Takishima, Isao [1 ]
Hirano, Mitsumasa [1 ]
Sano, Keita [1 ]
Nakamura, Takamitsu [1 ]
Kitta, Yoshinobu [1 ]
Obala, Jun-ei [1 ]
Kuglyama, Kiyotaka [1 ]
机构：
[1] Yamanashi Univ, Chuo, Japan
来源：
CIRCULATION | 2008年 / 118卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S1113 / S1113
页数：1
相关论文
共 50 条
  • [1] High Plasma Levels of Macrophage Migration Inhibitory Factor Adversely Affect Long-term Outcome in Patients With Acute Coronary Syndromes and With Impaired Glucose Tolerance or Type 2 Diabetes Mellitus
    Makino, Aritaka
    Ino, Yuri
    Kodama, Yasushi
    Takishima, Isao
    Hirano, Mitsumasa
    Sano, Keita
    Nakamura, Takamitsu
    Kitta, Yoshinobu
    Obata, Jun-ei
    Kugiyama, Kiyotaka
    CIRCULATION, 2009, 120 (18) : S398 - S398
  • [2] High plasma levels of macrophage migration inhibitory factor are associated with adverse long-term outcome in patients with stable coronary artery disease and impaired glucose tolerance or type 2 diabetes mellitus
    Makino, Aritaka
    Nakamura, Takamitsu
    Hirano, Mitsumasa
    Kitta, Yoshinobu
    Sano, Keita
    Kobayashi, Tsuyoshi
    Fujioka, Daisuke
    Saito, Yukio
    Watanabe, Kazuhiro
    Watanabe, Yosuke
    Kawabata, Ken-ichi
    Obata, Jun-ei
    Kugiyama, Kiyotaka
    ATHEROSCLEROSIS, 2010, 213 (02) : 573 - 578
  • [3] Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance
    Dogru, Teoman
    Sonmez, Alper
    Tasci, Ilker
    Bozoglu, Ergun
    Yilmaz, Mahmut Ilker
    Genc, Halil
    Erdem, Gokhan
    Gok, Mahmut
    Bingol, Necati
    Kilic, Selim
    Ozgurtas, Taner
    Bingol, Sezin
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2007, 76 (01) : 24 - 29
  • [4] Cardiovascular events and atherosclerosis in patients with type 2 diabetes and impaired glucose tolerance: What are the medical treatments to prevent cardiovascular events in such patients?
    Ishii, Hideki
    JOURNAL OF DIABETES INVESTIGATION, 2022, 13 (07) : 1114 - 1121
  • [5] Impaired glucose tolerance: a risk factor for type 2 diabetes and cardiovascular disease
    Chiasson, JL
    DIABETES RESEARCH AND CLINICAL PRACTICE, 1998, 40 : S1 - S2
  • [6] High Plasma Levels of Gremlin-1 and Macrophage Migration Inhibitory Factor, but Not Their Ratio, Indicate an Increased Risk for Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus
    Mueller, Karin A. L.
    Rath, Dominik
    Schmid, Martina
    Schoenleber, Heiko
    Gawaz, Meinrad
    Geisler, Tobias
    Mueller, Iris I.
    CLINICAL CARDIOLOGY, 2016, 39 (04) : 201 - 206
  • [7] Characteristics of Korean type 2 diabetes mellitus and impaired glucose tolerance patients
    Son, HY
    DIABETES MELLITUS: RECENT ADVANCES FOR THE 21ST CENTURY, 2000, 1209 : 15 - 18
  • [8] Autoimmune Thyroiditis, Type 2 Diabetes Mellitus, Impaired Fasting Glucose, Impaired Glucose Tolerance and Cardiovascular Risk Factors
    Neves, Celestino
    Alves, Marta
    Pereira, Miguel
    Ramalho, Renata
    Carvalho, Ema
    Pimentel, Isolina
    Carvalho, Davide
    Guimaraes, Cristina
    Ramos, Joao Pedro
    Delgado, Luis
    Medina, Jose Luis
    DIABETES, 2010, 59 : A356 - A356
  • [9] Acarbose in the prevention of cardiovascular disease in subjects with impaired glucose tolerance and type 2 diabetes mellitus
    Delorme, S
    Chiasson, JL
    CURRENT OPINION IN PHARMACOLOGY, 2005, 5 (02) : 184 - 189
  • [10] High molecular weight adiponectin and osteopontin plasma concentrations do not predict cardiovascular events in patients with type 2 diabetes mellitus
    Krzyzanowska, Katarzyna
    Aso, Yoshimasa
    Mittermayer, Friedrich
    Inukai, Toshihiko
    Schernthaner, Guntram
    DIABETES, 2008, 57 : A618 - A618
12345